罗格列酮对2型糖尿病高血压患者血清基质金属蛋白酶2及其组织抑制因子1的影响  

Effect of rosiglitazone on serum MMP-2 and TIMP-1 in diabetic hypertension

作　　者：周秀艳[1] 侯振江[2] 李艳华[1] 邢桂芝[3] 韩素桂[1] 于文霞[1] 楮金龙 

机构地区：[1]河北省唐山市人民医院检验科,063001 [2]沧州医学高等专科学校 [3]唐山市工人医院检验科

出　　处：《中国糖尿病杂志》2008年第11期667-669,共3页Chinese Journal of Diabetes

基　　金：唐山市科学技术研究与发展计划课题资助项目(04134623C)

摘　　要：目的观察2型糖尿病合并原发性高血压(DMEH)患者血清基质金属蛋白酶2(MMP-2)及其组织抑制因子1(TIMP-1)的水平及罗格列酮(RGZ)治疗后的变化。方法40例DMEH患者随机分成两组:⑴DMEH非RGZ治疗组20例(男10例,女10例);(2)DMEHRGZ治疗组20例(男8例,女12例)。采用酶联免疫吸附法测定MMP-2、TIMP-1及实验室相关指标,观察RGZ治疗前后MMP-2、TIMP-1水平变化及与非RGZ治疗组之间变化的差别。结果应用RGZ治疗组治疗16周后的血清MMP-2、TIMP-1水平分别为(37.9±3.9)μg/L和(410.0±80.9)μg/L,MMP-2水平较治疗前(27.5±4.3)明显升高(P<0.05);而TIMP-1水平较治疗前(468.1±100.6)明显降低(P<0.05)。结论RGZ治疗除能改善血糖及血压外,可升高MMP-2和降低TIMP-1水平。Objective To observe the effect of rosiglitazone on MMP-2 and TIMP-1 in the patients with diabetic hypertension. Methods 40 diabetic patients with essential hypertension（DMEH） were divided into 2 groups： （1）group A （n= 20） without rosiglitazone treatment; （2） group B（n= 20） undergoing rosiglitazone treatment. ELISA method was adopted to determine the levels of MMP-2 and TIMP-1,and the differences in MMP-2 and TIMP-1 between pre- and post-use of rosiglitazone were observed. Results At 16 weeks of the treatment by rosiglitazone, the level of MMP-2 was higher after treatment than before treatment [ （37.9± 3.9） vs（27. 5 ± 4.3） μg/L, P〈 0. 05], and the level of TIMP-1 was lower after treatment than before treatment[（410±81） vs（468±101）μg/L,P〈0. 01]. Conclusions Rosiglitazone not only improves blood sugar and blood pressure,but also raises the level of MMP-2 and reduces the level of TIMP-1.

关 键 词：罗格列酮 糖尿病 血清基质金属蛋白酶2 组织金属蛋白酶抑制因子1 

分 类 号：R587.1[医药卫生—内分泌] R563.1[医药卫生—内科学]